Page 39 - MemoriaBBN-Eng

www.ciber-bbn.es

To provide support to the preclinical development of research projects for identi-
General Objective
fying new therapeutic compounds by means of validation studies of new therapeutic

targets and/or nanotherapies by means of optical imaging and NMR technologies,
in addition to collaborating with hospitals and other centres of the National Health

System and with pharmaceutical companies in diagnostic research activities.

The functions of this platform include:
Purpose and
•
Analysing the phagocitic behaviour and interactions of cells in response to
functionality
therapeutic magnetic nanoparticulate agents; establishing possible infections
due to magnetotactic bacteria.

• Spectroscopies for in vivo applications; applications in fluids, tissues, and
biomaterials

•
Validating, viewing, following up on and quantifying quantification, in vivo

and in time real, the therapeutic factors used, as well as analysing treatment-

induced tissue regeneration

• Validating new therapeutic targets using optical imaging and NMR technolo-
gies

•
Viewing, following up on and quantifying cellular and genetic activities relating
to pathologies in a living organism in time real.

• Equipments in Instituto Universitario de Nanociencia de Aragón (INA) ...
Collaboration
• Minimally Invasive Surgery Centre Jesús Usón
with other
•
platforms
Image Unit in CIC biomaGUNE

In 2013, the units were internally evaluated intended for giving an economic in-
centive to units with the highest scores. The new internal evaluation protocol was

consolidated and started up in 2013.

One year later, the search for external funding was a priority in 2013 from both pu-

blic and private sources. The Programme was presented in international organisms
and partnering events, and in national enterprises, private research foundations

and public research organisms. Promotional material was distributed at different
visits to companies, research centres and industrial associations. This material was

also distributed through participation in the Spanish Technology Platform MATER-

PLAT and the Spanish Biotechnology Platform, the European BioRegions Council 13
(CEBR) and the recently created European project, IN2LifeSciences (IN2LS), which 20
T
promotes new relations between small- and mid-sized enterprises, on one hand, OR
P
and research organisms on the other. Participation in international infrastructures RE
such as Eurobioimaging was also promoted.
L
A
NU
N
The following events were attended:
A
N /
B
-B
• II Horizon Conference 2020 II Horizon Health Forum 2020 (Madrid). R
BE
• H2020 Conference Framework Programme Nov, Madrid. CI

• BioEurope Spring, March, Barcelona
39